Real-life comparative study on the effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps
A. TIOTIU (Nancy, France), P. Mendez-Brea (Santiago de Compostela, Spain), I. Ioan (Nancy, France), R. Romero-Fernandez (Santiago de Compostela, Spain), J. Oster (Colmar, France), T. Hoang (Colmar, France), P. Roux (Besançon, France), D. Ochoa-Gutierrez (Strasbourg, France), P. Bonniaud (Dijon, France), F. De Blay (Strasbourg, France), F. Gonzalez-Barcala (Santiago de Compostela, Spain)
Source: International Congress 2022 – Asthma treatment: real-world studies and other diseases
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. TIOTIU (Nancy, France), P. Mendez-Brea (Santiago de Compostela, Spain), I. Ioan (Nancy, France), R. Romero-Fernandez (Santiago de Compostela, Spain), J. Oster (Colmar, France), T. Hoang (Colmar, France), P. Roux (Besançon, France), D. Ochoa-Gutierrez (Strasbourg, France), P. Bonniaud (Dijon, France), F. De Blay (Strasbourg, France), F. Gonzalez-Barcala (Santiago de Compostela, Spain). Real-life comparative study on the effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps. 1335
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|